Posted by Michael Wonder on 21 Jun 2017
Agreement with ArjoHuntleigh Limited for the supply of medical devices used in the prevention of venous thromboembolism
21 June 2017 - PHARMAC is pleased to announce the approval of an agreement with ArjoHuntleigh for the supply of Medical devices used in the prevention of venous thromboembolism.
In summary, the effect of the decision is that:
- A range of 37 VTE Prevention devices will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 July 2017.
- DHB hospitals can purchase these devices from ArjoHuntleigh under the national agreement.
- For the DHBs that currently use these devices the agreement will deliver savings of approximately $380,000 per annum nationally, based on current usage.
